miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7.

The cytokine transforming growth factor (TGF)-β1 plays a central role in diabetic nephropathy (DN) with data implicating the miRNA (miR) miR-21 as a key modulator of its prosclerotic actions. In the present study, we demonstrate data indicating that miR-21 up-regulation positively correlates with the severity of fibrosis and rate of decline in renal function in human DN. Furthermore, concomitant analyses of various models of fibrotic renal disease and experimental DN, confirm tubular miR-21 up-regulation. The fibrotic changes associated with increased miR-21 levels are proposed to include the regulation of TGF-β1-mediated mothers against decapentaplegic homolog 3 (SMAD3)- and phosphoinositide 3-kinase (PI3K)-dependent signalling pathways via co-ordinated repression of mothers against decapentaplegic homolog 7 (SMAD7) and phosphatase and tensin homologue (PTEN) respectively. This represents a previously uncharacterized interaction axis between miR-21 and PTEN-SMAD7. Targeting of these proteins by miR-21 resulted in de-repression of the respective pathways as reflected by increases in SMAD3 and V-Akt murine thymoma viral oncogene homolog 1 (AKT) phosphorylation. Many of the changes typically induced by TGF-β1, including phosphorylation of signalling mediators, were further enhanced by miR-21. Collectively, these data present a unified model for a key role for miR-21 in the regulation of renal tubular extracellular matrix (ECM) synthesis and accumulation and provide important insights into the molecular pathways implicated in the progression of DN.

[1]  T. Tuschl,et al.  MicroRNA-21 in glomerular injury. , 2015, Journal of the American Society of Nephrology : JASN.

[2]  Naoki Nakagawa,et al.  Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. , 2015, The Journal of clinical investigation.

[3]  A. Tobar,et al.  Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy , 2014, Journal of Lipid Research.

[4]  J. Mi,et al.  MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation , 2013, Scientific Reports.

[5]  Xianzhong Xiao,et al.  MicroRNA-21 in Scleroderma Fibrosis and its Function in TGF-β- Regulated Fibrosis-Related Genes Expression , 2013, Journal of Clinical Immunology.

[6]  N. Pottier,et al.  Increased Circulating miR-21 Levels Are Associated with Kidney Fibrosis , 2013, PloS one.

[7]  H. Lan,et al.  Smad7 suppresses renal fibrosis via altering expression of TGF-β/Smad3-regulated microRNAs. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  R. Müller,et al.  Conditional loss of kidney microRNAs results in congenital anomalies of the kidney and urinary tract (CAKUT) , 2013, Journal of Molecular Medicine.

[9]  Xiao-ming Meng,et al.  miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes , 2013, Diabetologia.

[10]  B. Kasinath,et al.  TGFβ-Stimulated MicroRNA-21 Utilizes PTEN to Orchestrate AKT/mTORC1 Signaling for Mesangial Cell Hypertrophy and Matrix Expansion , 2012, PloS one.

[11]  L. Hunyady,et al.  Crosstalk between TGF-β signaling and the microRNA machinery. , 2012, Trends in pharmacological sciences.

[12]  V. Patel,et al.  MicroRNAs and fibrosis , 2012, Current opinion in nephrology and hypertension.

[13]  P. Pandolfi,et al.  The functions and regulation of the PTEN tumour suppressor , 2012, Nature Reviews Molecular Cell Biology.

[14]  C. Feschotte,et al.  Endogenous viruses: insights into viral evolution and impact on host biology , 2012, Nature Reviews Genetics.

[15]  Aaron N. Chang,et al.  MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways , 2012, Science Translational Medicine.

[16]  Merlin C. Thomas,et al.  Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. , 2012, Journal of the American Society of Nephrology : JASN.

[17]  A. Ghosh,et al.  PAI‐1 in tissue fibrosis , 2012, Journal of cellular physiology.

[18]  Xiao-ming Meng,et al.  Smad3-mediated upregulation of miR-21 promotes renal fibrosis. , 2011, Journal of the American Society of Nephrology : JASN.

[19]  Bo Wang,et al.  Diabetes Complications: The MicroRNA Perspective , 2011, Diabetes.

[20]  Falguni Das,et al.  MicroRNA-21 Orchestrates High Glucose-induced Signals to TOR Complex 1, Resulting in Renal Cell Pathology in Diabetes* , 2011, The Journal of Biological Chemistry.

[21]  M. Cooper,et al.  Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-β in diabetic nephropathy. , 2011, Kidney international.

[22]  Merlin C. Thomas,et al.  miR-200a Prevents Renal Fibrogenesis Through Repression of TGF-β2 Expression , 2010, Diabetes.

[23]  J. Iacomini,et al.  Identification of a microRNA signature of renal ischemia reperfusion injury , 2010, Proceedings of the National Academy of Sciences.

[24]  W. Filipowicz,et al.  Regulation of mRNA translation and stability by microRNAs. , 2010, Annual review of biochemistry.

[25]  M. Lindsay,et al.  MicroRNAs and the regulation of fibrosis , 2010, The FEBS journal.

[26]  N. Kaminski,et al.  miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis , 2010, The Journal of experimental medicine.

[27]  Jai Radhakrishnan,et al.  Pathologic classification of diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[28]  B. Harfe,et al.  The microRNA-processing enzyme dicer maintains juxtaglomerular cells. , 2010, Journal of the American Society of Nephrology : JASN.

[29]  F. Brosius,et al.  Abnormalities in signaling pathways in diabetic nephropathy , 2010, Expert review of endocrinology & metabolism.

[30]  Ziying Liu,et al.  Regulation of TGF-β signaling by Smad7 , 2009, Acta biochimica et biophysica Sinica.

[31]  J. Rossi,et al.  TGF-β activates Akt kinase via a microRNA-dependent amplifying circuit targeting PTEN , 2009, Nature Cell Biology.

[32]  E. Olson,et al.  Searching for miR-acles in cardiac fibrosis. , 2009, Circulation research.

[33]  Merlin C. Thomas,et al.  Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes , 2008, Diabetes.

[34]  G. Wolf,et al.  Cellular and Molecular Mechanisms of Proteinuria in Diabetic Nephropathy , 2007, Nephron Physiology.

[35]  S. Mader,et al.  Altered Endothelial Nitric Oxide Synthase Targeting and Conformation and Caveolin-1 Expression in the Diabetic Kidney , 2006, Diabetes.

[36]  L. Gesualdo,et al.  Pathogenetic mechanisms of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.

[37]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[38]  R. Atkins,et al.  Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). , 2001, The Journal of clinical investigation.

[39]  Denis Vivien,et al.  Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitor‐type 1 gene , 1998, The EMBO journal.

[40]  Š. Čikoš,et al.  Transformation of real-time PCR fluorescence data to target gene quantity. , 2009, Analytical biochemistry.